EOLS Evolus Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EOLS

Price (delayed)

$13.3

Market cap

$770.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.08

Enterprise value

$834.36M

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only ...

Highlights
EOLS's gross profit has surged by 52% year-on-year and by 9% since the previous quarter
Evolus's revenue has increased by 36% YoY and by 9% QoQ
The debt has surged by 70% year-on-year and by 25% since the previous quarter
Evolus's equity has decreased by 7% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.evolus.com
Peers: OMER OMGA

Key stats

What are the main financial stats of EOLS
Market
Shares outstanding
57.94M
Market cap
$770.65M
Enterprise value
$834.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.13
Earnings
Revenue
$202.09M
EBIT
-$47.68M
EBITDA
-$41.81M
Free cash flow
-$35.64M
Per share
EPS
-$1.08
Free cash flow per share
-$0.63
Book value per share
-$0.36
Revenue per share
$3.55
TBVPS
$2.12
Balance sheet
Total assets
$189M
Total liabilities
$209.69M
Debt
$126.55M
Equity
-$20.69M
Working capital
$64.13M
Liquidity
Debt to equity
-6.12
Current ratio
2.33
Quick ratio
1.93
Net debt/EBITDA
-1.52
Margins
EBITDA margin
-20.7%
Gross margin
69.5%
Net margin
-30.5%
Operating margin
-24.4%
Efficiency
Return on assets
-36%
Return on equity
N/A
Return on invested capital
-41.6%
Return on capital employed
-33.9%
Return on sales
-23.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EOLS stock price

How has the Evolus stock price performed over time
Intraday
0.61%
1 week
16.36%
1 month
-2.06%
1 year
60.05%
YTD
26.31%
QTD
-5%

Financial performance

How have Evolus's revenue and profit performed over time
Revenue
$202.09M
Gross profit
$140.53M
Operating income
-$49.23M
Net income
-$61.69M
Gross margin
69.5%
Net margin
-30.5%
EOLS's gross profit has surged by 52% year-on-year and by 9% since the previous quarter
The company's operating margin rose by 45% YoY and by 12% QoQ
The net margin rose by 39% year-on-year and by 11% since the previous quarter
Evolus's revenue has increased by 36% YoY and by 9% QoQ

Growth

What is Evolus's growth rate over time

Valuation

What is Evolus stock price valuation
P/E
N/A
P/B
N/A
P/S
3.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.13
The company's EPS rose by 19% YoY and by 3.6% QoQ
Evolus's equity has decreased by 7% QoQ
The P/S is 74% less than the 5-year quarterly average of 14.4 but 34% more than the last 4 quarters average of 2.8
Evolus's revenue has increased by 36% YoY and by 9% QoQ

Efficiency

How efficient is Evolus business performance
The ROIC has grown by 49% YoY and by 17% from the previous quarter
The company's return on sales rose by 46% YoY and by 14% QoQ
Evolus's ROA has increased by 3.5% from the previous quarter and by 3% YoY

Dividends

What is EOLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EOLS.

Financial health

How did Evolus financials performed over time
The total assets is 10% less than the total liabilities
The quick ratio has grown by 36% since the previous quarter and by 18% year-on-year
The company's total liabilities rose by 31% YoY and by 12% QoQ
The debt has surged by 70% year-on-year and by 25% since the previous quarter
Evolus's debt to equity has decreased by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.